Effects of Tumor Downstaging on Robotic Surgery Outcomes in Stage IIB-III Non-Small Cell Lung Cancer After Chemo-Immunotherapy

What this Trial Is About

Researchers are investigating whether tumor and lymph node downstaging after neoadjuvant chemo-immunotherapy is linked to better surgical outcomes in patients with clinical stage IIB-III non-small cell lung cancer NSCLC. This observational study focuses on patients undergoing robotic-assisted thoracic surgery and aims to understand if this downstaging improves surgery success and recovery. Participants receive neoadjuvant chemo-immunotherapy, which includes PD-1PD-L1 inhibitors combined with platinum-based chemotherapy, sometimes with added radiation therapy before surgery. After treatment, they undergo robotic-assisted lung surgery with systematic lymph node removal. The study collects data on surgical completeness, extent of resection, any conversion to open surgery, complications, hospital stay length, readmission, and mortality. During the study, researchers gather clinical, surgical, pathological, and postoperative outcome information. Participants have baseline and restaging chest scans before surgery, and follow-up extends to 90 days after surgery to monitor complications and recovery. The main outcome measured is complete tumor removal, with additional monitoring of hospital stay duration, postoperative problems, readmission rates, and mortality within 30 and 90 days.

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC